Part I Overview Information
United States Department of Health and Human Services (HHS)
Issuing Organization
Centers for Disease Control and Prevention (NCIRD/CDC), at http://www.cdc.gov/vaccines/about/default.htm
Participating Organizations
Centers for Disease Control and Prevention (CDC), at http://www.cdc.gov/
Components of Participating Organizations
National Center for Immunization and Respiratory Disease (NCIRD/CDC), at http://www.cdc.gov/vaccines/about/default.htm
Title Influenza Vaccine Efficacy in Tropical and Developing Countries (U01)
The policies,
guidelines, terms, and conditions of the HHS Centers for
Disease Control and Prevention (CDC) stated in this
announcement might differ from those used by the HHS
National Institutes of Health (NIH). If written guidance
for completing this application is not available on the CDC
website, then CDC will direct applicants elsewhere for that
information.
Authority
Sections
307 and 317(k)(1) of the Public Health Service Act (42
U.S.C. 242l and 247b(k)(1)), as amended
Announcement Type: New
Instructions for Submission of Electronic Research Applications:
NOTICE: Applications submitted in response to this Funding Opportunity Announcement (FOA) for Federal assistance May be submitted electronically through Grants.gov (http://www.grants.gov) using the SF424 Research and Related (R&R) forms and the SF424 (R&R) Application Guide.
This FOA must be read in conjunction with the application package instructions included with this announcement on Grants.gov/Apply for Grants (hereafter referred to as, Grants.gov/Apply.)
A registration process is necessary before submission, and applicants are strongly encouraged to start the process at least four weeks prior to the grant submission date. See Section IV.
Two steps are required for on time submission:
1) The application must be successfully received by Grants.gov no later than 5:00 p.m. Eastern Time on the application submission receipt date (see “Key Dates” below.)
2) Applicants must complete a verification step in the Electronic Research Administration (eRA Commons) within two business days of notification. Note: Since email can be unreliable, it is the responsibility of the applicant to periodically check on their application status in the eRA Commons.
Funding Opportunity Announcement (FOA) Number: RFA-IP08-002
Catalog of Federal Domestic Assistance Number(s): 93.283 Centers for Disease Control and Prevention – Investigations and Technical Assistance
Key
Dates
Release/Posted Date:
Earliest Anticipated Start Date(s): July 1, 2008
Additional Information to Be Available Date: Not applicable
Expiration Date: February 5, 2008
Due Date for E.O. 12372
Due no later than 60 days after the application receipt date.
Additional Overview Content
Funding Opportunity Announcement Glossary: FOA Glossary Terminology
Table of Contents
Part I Overview
Information
Part II Full Text
of Announcement
Section I.
Funding Opportunity Description
1. Research
Objectives
Section II. Award
Information
1.
Mechanism(s) of Support
2. Funds
Available
Section III.
Eligibility Information
1. Eligible
Applicants
A.
Eligible Institutions
2.Cost
Sharing or Matching
3.Other -
Special Eligibility Criteria
Section IV.
Application and Submission Information
1. Request
Application Information
2. Content
and Form of Application Submission
3. Submission
Dates and Times
A.
Receipt and Review and Anticipated Start Dates
1.
Letter of Intent
B.
Submitting an Application to CDC
C.
Application Processing
4.
Intergovernmental Review
5. Funding
Restrictions
6. Other
Submission Requirements
Section V.
Application Review Information
1. Criteria
2. Review and
Selection Process
A.
Additional Review Criteria
B.
Additional Review Considerations
C.
Sharing Research Data
D.
Sharing Research Resources
3. Anticipated
Announcement and Award Dates
Section VI. Award
Administration Information
1. Award
Notices
2.
Administrative and National Policy Requirements
A.
Cooperative Agreement
1.
Recipient Rights and Responsibilities
2.
HHS/CDC Responsibilities
3.
Collaborative Responsibilities
3. Reporting
Section VII.
Agency Contact(s)
1.
Scientific/Research Contact(s)
2. Peer
Review Contact(s)
3. Financial/
Grants Management Contact(s)
4. General
Questions Contact(s)
Section VIII.
Other Information - Required Federal Citations
Part II - Full Text of Announcement
Section I. Funding Opportunity Description
1. Research Objectives
The National Center for Immunization and Respiratory Diseases (NCIRD) of CDC within HHS is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2010" and to measuring program performance as stipulated by the Government Performance and Review Act (GPRA). This FOA addresses “Healthy People 2010” priority area(s) of Immunization and Infectious Diseases and is in alignment with the performance goal(s) to Protect Americans from Infectious Diseases. For more information, www.healthypeople.gov. and
http://intra-apps.cdc.gov/fmo/
The NCIRD Influenza Division (ID) is seeking a cooperative agreement for studies to evaluate the efficacy or effectiveness of influenza vaccine among children and the indirect protective effects for unvaccinated persons in the same community in one or more tropical and developing countries. Funding preference will be given to proposals for studies to be conducted in tropical, developing countries over non-tropical, developing countries. Proposals to conduct studies in developed countries will not be considered for funding.
A limited number of studies have suggested that influenza vaccination of select groups in a population provides protection to both vaccinated and unvaccinated persons, including those who respond poorly to vaccination, by decreasing transmission within a community to susceptible persons. Studies that have been conducted to assess the indirect effects of influenza vaccination have generally focused on the indirect effects among household members when children are vaccinated or on the effects of nursing home residents when health-care workers are vaccinated. Apart from an observational study that was conducted from a community perspective during the 1968 pandemic, few data are available to evaluate the effects of influenza vaccination on rates of illness in a community among non-vaccinated persons. Furthermore, no information is available from tropical, developing countries, where influenza vaccine use remains limited. In these countries, differences in social interactions, population density, household composition, and school attendance could alter the transmission characteristics of influenza compared to those in the United States and other developed countries in temperate climates.
As the next influenza pandemic could arise in a tropical, developing country, such information is critical to effective planning and preparedness, but will also add to the general understanding of the dynamic interplay between influenza transmission, social structure, and population immunity. Information obtained from such studies will also provide important data on strategies for the use of influenza vaccine during a pandemic, when the supply of vaccine will likely be limited. Results from these studies will also provide important information on the epidemiology and disease burden of influenza in tropical regions, and on the potential benefits of seasonal vaccination programs in developing countries.
This research will assess the effectiveness of influenza vaccine against laboratory-confirmed influenza among children and the indirect effects of influenza vaccination among unvaccinated persons in the same community. The study should compare rates of the relevant outcomes among children selected to receive influenza vaccine compared with those selected not to receive vaccine. Persons not selected to receive an influenza vaccine should receive some benefit from participation, such as an alternate vaccine with similar dose schedule. In addition, the proposed studies should determine the effects of vaccination in reducing laboratory-confirmed influenza among unvaccinated persons in the community, other household members, and persons who are living in households without children. Selection of vaccinees will be at the community level, not the individual level, so that all members of the target age group in each community should be offered either influenza vaccine or a control vaccine. The populations chosen for the studies should be sufficiently large and separate that the study can demonstrate indirect protection of influenza vaccination of children and sufficiently distinct such that mixing of populations between intervention and non-intervention areas is limited. The treatment and control communities should also be expected to have similar rates of ILI and of health outcomes associated with ILI based on demographic characteristics, geographic proximity and health utilization patterns. The researchers should enumerate each area such that they can make population-based estimates of influenza disease outcomes.
Influenza vaccination of all groups in the study populations should be consistent with the countries’ National Government vaccination policies and practices.
Studies should begin with the 2008-2009 influenza season, based on the timing of funding. The study should take place during three consecutive influenza seasons, and vaccination should occur before each season.
All of the following objectives must be addressed in the research plan of the application:
• Determine the efficacy or the effectiveness of influenza vaccination in children six months of age through primary school (age about 10 years) on decreasing the incidence of laboratory-confirmed influenza in the children; and
Determine the indirect effects of influenza vaccination on laboratory-confirmed influenza among unvaccinated individuals who are living in the same community (i.e., whether incidence of influenza is decreased among these individuals) using an appropriate study design (e.g. an observer-blinded, randomized, placebo-controlled study). Applications should include a non-vaccine comparison group, and children who do not receive vaccine must receive a direct benefit from being in the study (such as an alternative vaccine). Observers who collect clinical outcome data should be blinded as to whether the participant is in the placebo or intervention arm of the study.
• Proposals should demonstrate the ability to enroll and monitor sufficient numbers of persons in intervention and non-intervention communities in order to have adequate power to detect 25% indirect protection in unvaccinated members of the vaccinated community.
• Define the rates and epidemiological characteristics of influenza disease outcomes in persons of all ages who are living in the study communities, including the incidence of severe disease, such as hospitalization;
• Conduct laboratory testing for influenza using viral culture and/or reverse transcriptase polymerase chain reaction (RT-PCR) testing among persons in intervention and non-intervention communities who meet pre-determined criteria for testing based on symptoms.
• Describe the clinical presentations of influenza disease, including co-morbid conditions and influenza-related complications, in the study population.
• Describe the impact of vaccination on non-laboratory-confirmed syndromic outcomes, such as influenza-like illness, febrile respiratory illness, and pneumonia.
• Detect in a timely and sensitive manner any adverse events related to vaccine implementation in the population.d Purpose Information Here
See Section VIII,
Other Information - Required Federal Citations, for policies
related to this announcement.
Section II. Award Information
1. Mechanism(s) of Support
This funding opportunity will use the U01 activity code.
The HHS/CDC U01 is a cooperative agreement assistance instrument. Under the U01 assistance instrument, the Recipient Organization retains the primary responsibility and dominant role for planning, directing, and executing the proposed project, and with HHS/CDC staff is substantially involved as a partner with the Recipient Organization, as described in Section VI.2.A., "Cooperative Agreement”.
2. Funds Available
The participating Centers, Institutes and Offices (CIO)(s) of NCIRD intends to commit approximately $2,500,000 in direct and indirect costs in fiscal year (FY)2008 to fund 1 - 2 applications. The total project period is 3 years and funding may vary by year being more or less than the year one award. Each applicant may request up to $1,250,000 in total costs including direct and indirect for the first 12 months. The estimated total project funding for each grantee is approximately $4,000,000 for the 3 year project period. Funding the cost of vaccine is the responsibility of the awardee (s). HHS/CDC will not entertain proposals over the funding limit with the expectation that applicants will propose to make-up any additional cost with in kind donations, such as donated vaccine. Funding may vary by year and be more or less than the year 1 budget. The anticipated start date for new awards is July 1, 2008.
All estimated funding amounts are subject to availability of funds.
If an applicant requests a funding amount greater than the ceiling of the award range, HHS/CDC will consider the application non-responsive, and it will not enter into the review process. HHS/CDC will notify the applicant that the application did not meet the submission requirements.
Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. Although the financial plans of the CIO (s) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds and the receipt of a sufficient number of meritorious applications.
Section III. Eligibility Information
1.
Eligible Applicants
1.A. Eligible Institutions
You may submit an application(s) if your organization has any of the following characteristics:
A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If you are applying as a bona fide agent of a state or local government, you must provide a letter from the state or local government as documentation of your status. Attach this documentation behind the first page of your application form or for electronic applications, use a PDF file and attach as “Other Documents” and label as appropriate.
2. Cost
Sharing or Matching
Cost sharing or matching is not required
3. Other-Special Eligibility Criteria
Applications for studies must include letters of support
from authorized representatives of partners whose
cooperation and/or approval will be important. These
include, but are not limited to, letters of endorsement from
the Ministry of Health of the country concerned. However,
applications must demonstrate collaboration with National
public-health and medical institutions and the WHO National
Influenza Laboratory. The PD/PI must have prior experience
in conducting large community, epidemiologic studies in
tropical and/or developing countries and have published
study findings in peer-reviewed scientific journals. PI’s
with experience in conducting studies on vaccine
effectiveness and/or viral respiratory illness would be
preferred.
Funding preference will be given to proposals with studies to be conducted in tropical developing countries over non-tropical developing countries.
Proposals to conduct studies in developed countries will not be considered for funding.
Applicants must agree to share influenza isolates derived from the study with HHS/CDC and the WHO.
Applicants must indicate knowledge of influenza-related projects currently underway or planned for the country in which the studies are planned and show linkages with and avoid duplication of other, HHS-funded, influenza-related research projects in the same country.
Studies must be conducted in country with a WHO National Influenza Center Laboratory that has submitted influenza viruses to WHO Collaborating Centers during each of the past two years, and should demonstrate evidence of this in the proposal. Applicants must include collaboration with National public-health and the relevant WHO National Influenza Center in their study plans and evidence of such collaboration must accompany the application package in the form of letters from National Government health official(s).
If your application is incomplete or non-responsive to the special requirements listed in this section, it will not enter into the review process.
Section IV. Application and Submission Information
To download a SF424 (R&R) Application Package and SF424 (R&R) Application Instructions for completing the SF424 (R&R) forms for this FOA, link to Grants.gov/Apply and follow the directions provided on that Web site.
A one-time registration is required for institutions/organizations at the following:
·
Grants.gov Get Registered,http://www.grants.gov/applicants/get_registered.jsp·
eRA Commons Prepare to Apply, http://era.nih.gov/ElectronicReceipt/preparing.htmIMPORTANT: both the applicant organization, as well as, the PD/PI must register in eRA Commons for an application to be accepted electronically. The Credentials Log-In, referenced in Section IV. 2. Content and Form of Application Submission, is obtained through Step #3 in the required actions below.
PD/PIs should work with their institutions/organizations to make sure they are registered in the eRA Commons.
The following three steps are required before an applicant institution/organization can submit an electronic application, as follows:
1) Organizational/Institutional Registration in Grants.gov Get Registered, http://www.grants.gov/applicants/get_registered.jsp
2) Organizational/Institutional Registration in the eRA Commons Prepare to Apply, http://era.nih.gov/ElectronicReceipt/preparing.htm
3) Project Director/Principal Investigator (PD/PI) Registration in the eRA Commons: Refer to the NIH eRA Commons System (COM) Users Guide.
Note that if a PD/PI is also an HHS peer-reviewer with an Individual DUNS and CCR registration, that particular DUNS number and CCR registration are for the individual reviewer only. These are different than any DUNS number and CCR registration used by an applicant organization. Individual DUNS and CCR registration should be used only for the purposes of personal reimbursement and should not be used on any grant applications submitted to the Federal Government.
Several of the steps of the registration process could take four weeks or more. Therefore, applicants should immediately check with their business official to determine whether their organization/institution is already registered in both Grants.gov and the eRA Commons. The HHS/CDC strongly encourages applicants to use the Grants.gov electronic applications process and have organizations and PD/PIs complete all necessary registrations.
1. Request Application
Information
Applicants must
download the SF424 (R&R) application forms and SF424 (R&R)
Application Guide for this FOA through
Grants.gov/Apply.
Note: Only the
forms package directly attached to a specific FOA can be
used. You will not be able to use any other SF424 (R&R)
forms (e.g., sample forms, forms from another FOA); although
some of the "Attachment" files may be useable for more than
one FOA.
For
further assistance, contact PGO TIMS: Telephone
770-488-2700, Email: PGOTIM@cdc.gov
HHS/CDC
Telecommunications for the hearing impaired: TTY
770-488-2783.
2.
Content and Form of Application Submission
Prepare all applications using the SF424 (R&R) application forms and in accordance with the
SF424 (R&R) Application Guide (MS Word or PDF).The SF424 (R&R) Application Guide is critical to submitting a complete and accurate application to HHS/CDC. There are fields within the SF424 (R&R) application components that, although not marked as mandatory, are required by HHS/CDC (e.g., the “Credential” log-in field of the “Research & Related Senior/Key Person Profile” component must contain the PD/PI assigned eRA Commons User ID). Agency-specific instructions for such fields are clearly identified in the Application Guide. For additional information, see “Tips and Tools for Navigating Electronic Submission” on the front page of “Electronic Submission of Grant Applications.”
The SF424 (R&R) application is comprised of data arranged in separate components. Some components are required, others are optional. The forms package associated with this FOA in Grants.gov/Apply will include all applicable components, mandatory and optional. A completed application in response to this FOA will include the following components:
Required Components:
SF424 (R&R)
(Cover component)
Research & Related Project/Performance Site Locations
Research & Related Other Project Information
Research & Related Senior/Key
Person
Research & Related Budget
PHS398 Cover Page Supplement
PHS398 Research Plan
PHS398 Checklist
Optional
Components:
PHS398 Cover
Letter File
Research & Related Sub award Budget Attachment(s) Form
Note: While both budget components are included in the SF424
(R&R) forms package, the CDC
U01
(activity code) uses ONLY the detailed
Research & Related
Budget. (Do not use the PHS 398
Modular Budget.)
Foreign
Organizations
Several special provisions apply to applications submitted by foreign organizations:
·
Charge back of customs and import fees is not allowed.·
Format: every effort should be made to comply with the format specifications which are based upon a standard US paper size of 8.5" x 11".·
Organizations must comply with Federal/CDC policies on human subjects, animals, and biohazards.·
Organizations must comply with Federal/CDC biosafety and biosecurity regulations. See Section VI. 2. Administrative Requirements http://oerdbdev.od.nih.gov/AGS/Admin/BoilerPlate/ShowDraftRFA.cfm, "Cooperative Agreement Terms and Conditions of Award".·
Proposed research should provide special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions in other countries that are not readily available in the United States or that augment exiting U.S. resources.NATO Commercial and Governmental Entity (NCAGE) Code are required for foreign organizations only. See below for instructions:
For help from within the U.S., call 1-888-227-2423
For help from outside the U.S., call 1-269-961-7766
Email NCAGE@dlis.dla.mil for any problems in getting an
NCAGE code
3. Submission Dates and Times
See Section IV.3.A for details
3. A. Submission, Review and Anticipated Start Dates
Letter of Intent
Receipt Date:
N/A
Application
Submission Receipt Date(s):
February 4, 2008
Peer Review
Date(s):
March-April 2008
Council Review
Date(s):
April-May 2008
Earliest Anticipated Start Date(s): July 1, 2008
3.A.1. Letter of Intent
A letter of intent is not applicable to this funding opportunity announcement.
3.B. Submitting an Application to CDC
If the instructions in this announcement differ in any way from the SF424 R&R instructions, follow the instructions in this announcement.
To submit an application in response to this FOA, applicants should access this FOA via Grants.gov/Apply and follow steps 1-4. If submittal of the application is done electronically through Grants.gov (http://www.grants.gov), the application will be electronically time/date stamped by Grants.gov. The applicants’ Authorized Organization Representative (AOR) will receive an e-mail notice of receipt from eRA Commons and Grants.gov when HHS/CDC receives the application.
All requested information must be received in the HHS/CDC Procurement and Grants Office by 5:00 p.m. Eastern Time on the deadline date. If an applicant submits materials by the United States Postal Service or commercial delivery service, you must ensure that the carrier will be able to guarantee delivery by the closing date and time. If HHS/CDC receives your submission after closing because of : (1) carrier error, when the carrier accepted the package with a guarantee for delivery by the closing date and time, or (2) significant weather delays or natural disasters, you have the opportunity to submit documentation of the carrier’s guarantee. If the documentation verifies a carrier problem, HHS/CDC will consider the submission as having been received by the deadline.
This announcement is the definitive guide on Letter Of Intent (LOI) and application content, submission address, and deadline. It supersedes information provided in the application instructions. If your application does not meet the deadline described in Section IV.3.A, it will not be eligible for review, and HHS/CDC will discard it. You will receive notification that you did not meet the submission requirements.
Otherwise, HHS/CDC will not notify you upon receipt of your
paper submission. If you have a question about the receipt
of your application, first contact your courier. If you
still have a question, contact the PGO-TIMS staff at:
770-488-2700. Before calling, please wait two to three days
after the submission deadline. This will allow time for
HHS/CDC to process and log submissions.
If submitting a paper application, it must be prepared using the SF424 R&R instructions for preparing a research grant application. Submit a signed, typewritten original of the application and all appendices, including the checklist, and three signed photocopy(s) to the following address:
Technical Information Management Section – IP08-002
CDC, Procurements and Grants Office
U.S. Department of Health and Human Services
2920 Brandywine Road
Atlanta, GA 30341
Phone: 770-488-2700 EST
3.C. Application Processing
HHS/CDC must receive
applications on
or before 5:00 P.M. Eastern Time on the application
submission date(s) described above (Section IV.3.A.). If
HHS/CDC receives an application after that submission date
and time, the application may be delayed in the review
process or not reviewed.
Once an application package has been successfully submitted through Grants.gov, any errors have been addressed, and the assembled application has been created in the eRA Commons, the PD/PI and the Authorized Organization Representative/Signing Official (AOR/SO) have two business days to view the application image.
· If everything is acceptable, no further action is necessary. The application will automatically move forward for processing by the CDC, PGO, Technical Information Management Section, after two business days.
· Prior to the submission deadline, the AOR/SO can “Reject” the assembled application and submit a changed/corrected application within the two day viewing window. This option should be used if the AOR/SO determines that warnings should be addressed. Reminder: warnings do not stop further application processing. If an application submission results in warnings (but no errors) it will automatically move forward after two business days if no action is taken. Please remember that some warnings may not be applicable or may need to be addressed after application submission.
· If the two day window falls after the submission deadline, the AOR/SO will have the option to “Reject” the application if, due to an eRA Commons or Grants.gov system issue, the application does not correctly reflect the submitted application package (e.g., some part of the application was lost or didn’t transfer correctly during the submission process). The AOR/SO should first contact the eRA Commons Helpdesk to confirm the system error, document the issue, and determine the best course of action. HHS/CDC will not penalize the applicant for an eRA Commons or Grants.gov system issue.
· If the AOR/SO chooses to “Reject” the image after the submission deadline for a reason other than an eRA Commons or Grants.gov system failure, a changed/corrected application still can be submitted but it will be subject to the CDC late policy guidelines and may not be accepted. The reason for this delay should be explained in the cover letter attachment and must refer only to Commons errors and/or technical errors.
· Both the AOR/SO and PD/PI will receive e-mail notifications when the application is rejected or the application automatically moves forward in the process after two days.
Upon receipt, applications will be evaluated for completeness and responsiveness by the Coordinating Center for Infectious Diseases (CCID) and HHS/CDC Procurement and Grants Office (PGO). HHS/CDC will not review incomplete and non-responsive applications.
There will be an acknowledgement of receipt of applications from Grants.gov and the eRA Commons.
4. Intergovernmental Review
Your application is subject to Intergovernmental Review of Federal Programs, as governed by Executive Order (EO) 12372. This order sets up a system for state and local governmental review of proposed federal assistance applications. You should contact your state single point of contact (SPOC) as early as possible to alert the SPOC to prospective applications, and to receive instructions on your state’s process. Click on the following link to get the current SPOC list: http://www.whitehouse.gov/omb/grants/spoc.html.
5. Funding Restrictions
All HHS/CDC awards are subject to the terms and conditions, cost principles, and other considerations described in the HHS Grants Policy Statement.
Restrictions, which applicants must take into account while writing their budgets, are as follows:
· Funds relating to the conduct of research will be restricted until the appropriate assurances and Institutional Review Board approvals are in place and a Notice of Award is issued lifting the restriction. Thus, it is in the best interest of applicants to have a fully developed study protocol, consent forms, and data collection instruments in hand so that a the protocol can be rapidly reviewed by the IRB of the awardee’s institution and HHS/CDC’s IRB in order to begin the study prior to the 2008-09 influenza season. · Reimbursement of pre-award costs is not allowed. · Specific language for international announcements is posted on the PGO intranet site: http://pgo.cdc.gov/pgo/ViewHome.do
6. Other Submission Requirements
Awardees upon acceptance of Notice of Award (NoA), must agree to the "Cooperative Agreement Terms and Conditions of Award" in Section VI. "Award Administration Information”.
Applicants’ research plan(s) should address activities they will conduct over the entire project period.
The HHS/CDC requires the PD/PI to fill in his/her eRA Commons User ID in the “PROFILE – Project Director/Principal Investigator” section, “Credential” log-in field of the “Research & Related Senior/Key Person Profile” component. The applicant organization must include its DUNS number in its Organization Profile in the eRA Commons. This DUNS number must match the DUNS number provided at CCR registration with Grants.gov. For additional information, see Registration FAQs – Important Tips -- Electronic Submission of Grant Applications.
Research Plan Component Sections
While each section of the Research Plan component needs to be uploaded separately as a PDF attachment, applicants are encouraged to construct the Research Plan component as a single document, separating sections into distinct PDF attachments just before uploading the files. This approach will enable applicants to better monitor formatting requirements such as page limits. All attachments must be provided to HHS/CDC in PDF format, filenames must be included with no spaces or special characters, and a PDF extension must be used. Do not include any information in a header or footer of the attachments. A header will be system-generated that references the PD/PI. Page numbers for the footer will be system-generated in the complete application, with all pages sequentially numbered; therefore, do not number the pages of your attachments. Your research plan must not exceed 25 pages. If your research plan exceeds the page limitation, your application may be considered unresponsive and ineligible for review.
The following materials may be included in the Appendix:
Up to Five publications, manuscripts (accepted for publication), abstracts, patents, or other printed materials directly relevant to the proposed project. Do not include manuscripts submitted for publication. Applicants should refer to instruction guides and specific Funding Opportunity Announcements (FOAs) to determine the appropriate limit on the number of publications that may be submitted for a particular program. Note that not all grant activity codes allow the inclusion of publications.
·
Publications in press: Include only a publication list with a link to the publicly available on-line journal article or the NIH Pub Med Central (PMC) submission identification number. Do not include the entire article.·
Manuscripts accepted for publication but not yet published: The entire article may be submitted electronically as a PDF attachment.·
Manuscripts published but a publicly available online journal link is not available: The entire article may be submitted electronically as a PDF attachment.·
Surveys, questionnaires, data collection instruments, clinical protocols, and informed consent documents.·
Graphic images of gels, micrographs, etc. provided that the image (may be reduced in size) is also included within the (stated) page limit of Items 2-5 of the Research Plan component. No images may be included in the Appendix that are not also represented within the Research Plan.
Please note the following restriction on appendix attachments: The Research Plan Appendix attachments are limited to 10 attachments. Appendices are uploaded as attachments in the PHS 398 Research Plan form, in field #18, within the electronic application package. An applicant will receive an error message if the number of appendix attachments exceeds 10, which will result in an unsuccessful submission of the application. You may include more than one publication, or other allowable appendix material, within one attachment; however, do not let your attachments exceed 10.”
Do not to use the Appendix to circumvent the page limitations of the Research Plan component. An application that does not observe the relevant policies and procedures may not be considered in the review process. Applicants are reminded to review specific FOAs for any additional program-specific guidance on Appendix material and other application requirements.
Plan for Sharing Research Data
The precise content of the data-sharing plan will vary, depending on the data being collected and how the investigator is planning to share the data. Applicants should describe briefly the expected schedule for data sharing, the format of the final dataset, the documentation they will provide, whether or not any analytic tools also will be provided, whether or not a data-sharing agreement will be required and, if so, a brief description of such an agreement (including the criteria for deciding who can receive the data and whether or not the awardee will place any conditions on their use), and the mode of data sharing (e.g., under their own auspices by mailing a disk or posting data on their institutional or personal website, through a data archive or enclave). References to data sharing may also be appropriate in other sections of the application.
All applicants
must include a plan for sharing research data in their
application. The HHS/CDC data sharing policy is available at
http://www.cdc.gov/od/pgo/funding/ARs.htm under
Additional Requirements 25 Release and Sharing of Data. All
investigators responding to this funding opportunity should
include a description of how final research data will be
shared, or explain why data sharing is not possible.
The
reasonableness of the data sharing plan or the rationale for
not sharing research data will be assessed by the reviewers.
However, reviewers will not factor the proposed data sharing
plan into the determination of scientific merit or the
priority score.
Sharing Research Resources
HHS
policy requires that grant award recipients make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication (see the HHS Grants Policy Statement http://www.hhs.gov/grantsnet/docs/HHSGPS_107.doc.) Investigators responding to this funding opportunity should include a plan for sharing research resources addressing how unique research resources will be shared or explain why sharing is not possible.
Section V. Application Review Information
1.
Criteria
Only the review
criteria described below will be considered in the review
process.
·
Scientific merit of the proposed project as determined by peer review·
Availability of funds·
Relevance of program priorities and the priorities of the U.S. Department of Health and Human Services · Applicants for research to be conducted in tropical developing countries will be funded prior to funding those from non-tropical developing countries even if the latter rank higher than the former. Proposals for research to be conducted in developed countries will not be considered for funding. · Relevance of program priorities and the priorities of the U.S. Department of Health and Human Services under the National Strategy for Pandemic Influenza · Applications that do not have collaboration and support from the National Influenza Center in the country from which the study is being proposed as demonstrated by a letter of support will not be funded. · The PI and other co-investigators must have prior experience in conducting large community, epidemiologic studies in developing countries and have published study findings in peer-reviewed scientific journals or the application will not be funded. · PI’s with experience in conducting studies on vaccine effectiveness and/or viral respiratory illness may be funded over those that rank higher but do not. · Applicants must demonstrate laboratory capability and capacity to perform influenza viral culture and influenza RT-PCR laboratory confirmation or they will not be funded. · If HHS/CDC is able to fund two awards, CDC may choose to fund the highest ranked application from different WHO Regions. · Applicants must be in a county with a WHO National Influenza Center Laboratory that submits influenza viruses on an annual basis to WHO Collaborating Centers, and must agree to share isolates with HHS/CDC and the WHO or they will not be funded.
2.
Review and Selection Process
Applications that
are complete and responsive to the FOA will be evaluated for
scientific and technical merit by an appropriate peer review
group convened by CCID or its designee in accordance with
the review criteria stated below.
As part of the
initial merit review, all applications will:
· Undergo a selection process in which only those applications deemed to have the highest scientific merit, generally the top half of applications under review, will be discussed and assigned a priority score
· Receive a written critique; and
· Receive a second level of review by HHS/CDC CCID
· Applications submitted in response to this FOA will compete for available funds with all other eligible applications. The criteria listed in Section V.1. will be considered in making funding decisions.
The goals of HHS/CDC-supported research are to advance the understanding of health promotion and the prevention of disease, injury, and disability, and enhance preparedness. In the written comments, evaluate the application to judge the likelihood the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed by the reviewers and considered in assigning the overall score, weighting them and weighted, as appropriate for each applications.
· Significance
· Approach
· Innovation
· Investigators
· Environment
Note that an
application does not need to be strong in all categories to
be judged likely to have major scientific impact and thus
deserve a high priority score. For example, an investigator
may propose to carry out important work that by its nature
is not innovative but is essential to move a field forward.
Significance:
Does this study address an important problem? If the
applicant achieves the aims of the application, how will it
advance scientific knowledge or clinical practice? What will
be the effect of these studies on the concepts, methods,
technologies, treatments, or preventative interventions that
drive this field?
Approach:
Are the conceptual or clinical framework, design, methods,
and analyses adequately developed, well integrated, well
reasoned, and appropriate to the aims of the project? Does
the applicant acknowledge potential problem areas and
consider alternative tactics?
Does the project
include adequate numbers of participants to address both the
objectives to estimate the direct and the indirect
effectiveness of influenza vaccine in the population? Does
the design include an appropriate comparison group? Does
the proposal sufficiently provide data to ensure that the
intervention and comparison groups are comparable with
respect to age distribution, household size and composition,
and health indicators? Are the intervention and
non-intervention communities sufficiently separate such that
mixing is likely to be limited? Is the laboratory
experienced in influenza virus culture and RT-PCR and have
the capacity to process specimens from a large study? Does
the proposal describe methods to assess for adverse events
associated with participation?
Innovation:
Is the project original and innovative? For example: Does
the project challenge existing paradigms or clinical
practice; address an innovative hypothesis or critical
barrier to progress in the field? Does the project develop
or employ novel concepts, approaches, methodologies, tools,
or technologies for this area?
Do the investigators
describe a reasonable plan to ensure that influenza testing
will be done appropriately and in a sufficiently timely
manner to support the study objectives? Do the data
management procedures and tools described in the proposal
seem reasonably well-designed to support the objectives? Is
the plan for estimating indirect protection sufficiently
well-described and appropriate to address this objective?
Investigators:
Are the investigators appropriately trained and well suited
to carry out this work? Is the work proposed appropriate to
the experience level of the principal investigator and other
researchers? Does the investigative team bring complementary
and integrated expertise to the project (if applicable)?
Have the PI and co-investigators demonstrated their ability
to conduct the proposed study based on prior experience and
evidenced by publication in scientific peer-reviewed
journals? Do they have experience conducting vaccine
studies and/or studies on influenza?
Environment:
Does the scientific environment in which the applicant will
do the work contribute to the probability of success? Do
the proposed studies benefit from unique features of the
scientific environment, or subject populations, or employ
useful collaborative arrangements? Is there evidence of
institutional support?
Is the study
adequately powered to address the study objectives? Are the
applicants able to describe the proposed study population
including: size, gender and age distribution of the
population, size of the annual birth cohort, current
influenza vaccine coverage rates, and current surveillance
in the population, characteristics of the populations that
might affect vaccine effectiveness or safety, and
characteristics that might affect the comparison of the two
groups?
2.A. Additional Review Criteria
In addition to
the above criteria, the following items will be considered
in the determination of scientific merit and the priority
score:
Protection of Human Subjects from Research Risk: When human subjects are involved, HHS/CDC will assess the available protections from research risk that relate to their participation in the proposed research. [see the Research Plan, Section 2, item 8 on Human Subjects in the SF424 (R&R)] http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm. Additional HHS/CDC Requirements under AR-1 Human Subjects Requirements are available on the Internet at the following address: http://www.cdc.gov/od/pgo/funding/ARs.htm.
Inclusion of Women and Minorities in Research:
Does the application adequately address the HHS/CDC Policy requirements regarding the inclusion of women, ethnic, and racial groups in the proposed research? This includes: (1) The proposed plan for the inclusion of both sexes and racial and ethnic minority populations for appropriate representation; (2) The proposed justification when representation is limited or absent; (3) A statement as to whether the design of the study is adequate to measure differences when warranted; and (4) A statement as to whether the plans for recruitment and outreach for study participants include the process of establishing partnerships with community(ies) and recognition of mutual benefits (see Section 2, item 9 Inclusion or Women and Minorities of the Research Plan component of the SF424 (R&R).
Care and Use of Vertebrate Animals in Research:
If applicants
plan to use vertebrate animals in the project, HHS/CDC will
assess the five items described under Section 2, item 12
Vertebrate Animals of the Research Plan component of the
SF424 (R&R).
Additional
HHS/CDC Requirements under AR-3 Animal Subjects Requirements
are available on the Internet at the following address:
http://www.cdc.gov/od/pgo/funding/ARs.htm.
Biohazards:
If applicants propose the applicant has proposed materials
or procedures that are potentially hazardous to research
personnel and/or the environment, HHS/CDC will determine if
the proposed protection is adequate.
2.B. Additional Review Considerations
Budget and Period
of Support: The reasonableness of the proposed budget and
the appropriateness of the requested period of support in
relation to the proposed research may be assessed by the
reviewers. Is the number of person months listed for the
effort of the PD/PI appropriate for the work proposed? Is
each budget category realistic and justified in terms of the
aims and methods? The evaluation of the budget should not
effect the priority score.
2.C. Sharing Research Data
Data Sharing Plan: HHS/CDC will assess the reasonableness of the data sharing plan. However, reviewers will not factor the proposed data sharing plan into the determination of scientific merit or the priority score. The presence of a data sharing plan will be part of the terms and conditions of the award. The funding organization will be responsible for monitoring the data sharing policy. Program staff will be responsible for the administrative review of the plan for sharing research data.
2.D.
Sharing Research Resources
HHS
policy requires that recipients of grant awards make unique research resources readily available for research purposes to qualified individuals within the scientific community after publication. Please see http://grants.nih.gov/grants/policy/gps/8postnew.htm#phs. Investigators responding to this funding opportunity should include a plan on sharing research resources.Program staff will be responsible for the administrative review of the plan for sharing research resources.
The adequacy of
the resources sharing plan will be considered by Program
staff of the funding organization when making
recommendations about funding applications. The
effectiveness of the resource sharing will be evaluated as
part of the administrative review of each non-competing
Grant Progress Report (HHS/PHS 2590
http://grants.nih.gov/grants/funding/2590/2590.htm).
See Section VI.3. Reporting.
3. Anticipated Announcement and Award Dates
Earliest anticipated award date is July 1, 2008
Section VI. Award Administration Information
1.
Award Notices
After the peer
review of the application is completed, the applicant
organization will receive a written critique called a
“Summary Statement.”
The
applicant organization and the PD/PI will be able to access
the Summary Statement via the eRA Commons.
HHS/CDC will contact t
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization. The NoA signed by the Grants Management Officer (GMO) is the authorizing document. HHS/CDC will mail and/or e-mail this document to the recipient fiscal officer identified in the application.
Selection of the application for award is not an authorization to begin performance. Any cost incurred before receipt of the NoA is at the recipient’s risk. These costs may be reimbursed only to the extent considered allowable pre-award costs. See also Section IV.5. Funding Restrictions.
2. Administrative and National Policy Requirements
The Code of
Federal Regulations 45 CFR Part 74 and Part 92 have details
about requirements. For more information on the Code of
Federal Regulations, see the National Archives and Records
Administration at the following Internet address:
http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
Additional requirements are available Section VIII. Other
Information of this document or on the HHS/CDC website at
the following Internet address:
http://www.cdc.gov/od/pgo/funding/ARs.htm. These will be
incorporated into the NoA by reference.
The following terms and conditions will be incorporated into the NoA and will be provided to the appropriate institutional official and a courtesy copy to the PD/PI at the time of award.
2.A. Cooperative Agreement
The following
terms of award are in addition to, and not in lieu of,
otherwise applicable Office of Management and Budget (OMB)
administrative guidelines, HHS grant administration
regulations at 45 CFR Parts 74 and 92 (Part 92 is applicable
when State and local Governments are eligible to apply), and
other HHS/CDC grant administration policies.
The
administrative and funding instrument used for this program
will be the cooperative agreement U01 an "assistance"
instrument (rather than an "acquisition" instrument), in
which substantial HHS/CDC programmatic involvement with the
awardees is anticipated during the performance of the
activities. Under the cooperative agreement, the HHS/CDC
purpose is to support and stimulate the recipients'
activities by involvement in and otherwise working jointly
with the award recipients in a partnership role; it is not
to assume direction, prime responsibility, or a dominant
role in the activities.
Consistent with this concept, the dominant role and prime
responsibility resides with the awardees for the project as
a whole, although specific tasks and activities may be
shared among the awardees and the HHS/CDC may share specific
tasks and activities, as defined above.
2.A.1. Recipient Rights and Responsibilities
The Recipient
will have the primary responsibility for the following:
• In collaboration with CDC scientists, develop a detailed study protocol and implementation plan that will accomplish the objectives in the research plan.
• Conduct the appropriate training of partners whose knowledge of the study and/or direct participation will be needed.
• Provide the necessary personnel and supplies to implement the study and analyze the results.
• Conduct the study in collaboration with CDC scientists;
• Prepare a detailed report of the conclusions;
• Present and submit the study (or its various components) for publication in a peer-reviewed journal within 12 months after completion.
• If culture is not the primary tool for laboratory confirmation, culture a sample of cases positive by PCR in order to obtain viral isolates for virus strain characterization and comparison to vaccine strains.
• Share influenza isolates with HHS/CDC and the WHO.
• Participate in conference calls with the HHS/CDC Project Scientists to collaborate on the development of the research protocols and provide progress updates and to attend one yearly in-person meeting with CDC co-investigators. This travel should be included in the proposed budget.
• Work with HHS/CDC scientists to refine protocols and to improve the science-based on reviewers’ comments in the summary statement.
• Obtaining all IRB approvals.
• Applications should include a non-vaccine comparison group, and children who do not receive vaccine must receive a direct benefit from being in the study (such as an alternative vaccine).
Recipient
Organization will retain custody of and have primary rights
to the information, data and software developed under this
award, subject to U.S. Government rights of access
consistent with current HHS/CDC policies.
2.A.2. HHS/CDC Responsibilities
An HHS/CDC
Project Scientist will have substantial programmatic
involvement that is above and beyond the normal stewardship
role in awards, as described below:
HHS/CDC will provide technical assistance as needed and may or may not include the following:
• Participate in design and implementation of studies,
• Provide background information on other relevant studies conducted at HHS/CDC or HHS National Institutes of Health,
• Provide advice about epidemiology of influenza, and about testing for influenza,
• Provide assistance with laboratory protocols and in identifying sources of reagents,
• Provide antigenic and genetic characterization of a sample of influenza isolates,
• Participate in interpretation of results, dissemination and publication of results,
• Participate in the development of a research protocol for IRB review by all cooperating institutions that are participating in the research project, including the HHS/CDC IRB. The HHS/CDC IRB will review the protocol initially and annually until the research project is completed, and
• Monitor and evaluate scientific and operational accomplishments of this project through frequent telephone contact, review of technical reports, and interim data analyses. Based on this, HHS/CDC will make recommendations aimed at solving problems and improving the quality and timeliness of the research activities.
Additionally, an
HHS/CDC agency program official or CIO program director will
be responsible for the normal scientific and programmatic
stewardship of the award and will be named in the NoA.
3. Reporting
Recipient Organization must provide HHS/CDC with an original, plus two hard copies of the following reports:
1. Non-Competing Grant Progress Report, (use form PHS 2590, posted on the HHS/CDC website, http://www.cdc.gov/od/pgo/funding/forms.htm and at http://grants.nih.gov/grants/funding/2590/2590.htm, no less than 120 days prior to the end of the current budget period. The progress report will serve as the non-competing continuation application. 2. Financial status report, no more than 90 days after the end of the budget period. 3. Final financial and performance reports, no more than 90 days after the end of the project period.
Recipient Organization must forward these reports by the U.S. Postal Service or express delivery to the Grants Management Specialist listed in the “Agency Contacts” section of this FOA.
Although the financial plans of the HHS/CDC CIO(s) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds, evidence of satisfactory progress by the recipient (as documented in required reports) and the determination that continued funding is in the best interest of the Federal government.
Section VII. Agency Contacts
HHS/CDC
encourages your inquiries concerning this FOA and welcomes the opportunity to answer questions from potential applicants. Inquiries can fall into three areas: scientific/research, peer review, and financial or grants management issues:Dr. Shoukat Qari
Office of Extramural Research
Coordinating Center for Infectious Diseases
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services
1600 Clifton Road, MS E-05
Atlanta, GA 30333
Telephone: (404) 639-8942
FAX: (404) 639-2469
Email: SQari@cdc.gov
2. Peer Review Contacts:
Dr. Juliana Cyril
Office of Public Health Research
Centers for Disease Control and Prevention
U.S. Department of Health and Human Services
1600 Clifton Road
Atlanta, GA 30333
Telephone: (404) 639-4639
Fax: 404-639-4903
Email:
JCyril@cdc.gov
3. Financial or Grants Management Contacts:
Mr. Steward Nichols
Grants Management Specialist
Procurement and Grants Office
Center for Disease Control and Prevention
U.S. Department of Health and Human Services
Street Address
2920 Brandywine Rd. Rm. 2707
Colgate Building MS K-75
Atlanta, GA 30341-4146
Telephone: (770) 488-2788
Fax: (770) 488-2688
Email:
shn8@cdc.gov
4.
General Questions Contacts:
Technical
Information Management Section
CDC Procurement and Grants Office
U.S. Department of Health and Human Services
2920 Brandywine Road
Atlanta, GA 30341
Telephone: 770-488-2700
Email: PGOTIM@cdc.gov
Section VIII. Other Information
Required Federal Citations
Human Subjects
Protection
Federal
regulations (45 CFR Part 46) require that applications and
proposals involving human subjects must be evaluated with
reference to the risks to the subjects, the adequacy of
protection against these risks, the potential benefits of
the research to the subjects and others, and the importance
of the knowledge gained or to be gained (http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm).
Additional HHS/CDC Requirements under AR-1 Human Subjects
Requirements can be found on the Internet at the following
address:
http://www.cdc.gov/od/pgo/funding/ARs.htm.
Use of Animals in
Research
Recipients of PHS
support for activities involving live, vertebrate animals
must comply with the PHS Policy on Humane Care and Use of
Laboratory Animals (http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf)
as mandated by the Health Research Extension Act of 1985 (http://grants.nih.gov/grants/olaw/references/hrea1985.htm),
and the USDA Animal Welfare Regulations (http://www.nal.usda.gov/awic/legislat/usdaleg1.htm)
as applicable. Additional HHS/CDC Requirements under AR-3
Animal Subjects Requirements can be found on at
http://www.cdc.gov/od/pgo/funding/ARs.htm.
Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research
It is the policy of the Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR) to ensure that individuals of both sexes and the various racial and ethnic groups will be included in CDC/ATSDR-supported research projects involving human subjects, whenever feasible and appropriate. Racial and ethnic groups are those defined in OMB Directive No. 15 and include American Indian or Alaska Native, Asian, Black or African American, Hispanic or Latino, Native Hawaiian or Other Pacific Islander. Applicants shall ensure that women, racial and ethnic minority populations are appropriately represented in applications for research involving human subjects. Where clear and compelling rationale exist that inclusion is inappropriate or not feasible, this situation must be explained as part of the application. This policy does not apply to research studies when the investigator cannot control the race, ethnicity, and/or sex of subjects. Further guidance to this policy is contained in the Federal Register, Vol. 60, No. 179, pages 47947-47951, and dated Friday, September 15, 1995.
INCLUSION OF
PERSONS UNDER THE AGE OF 21 IN RESEARCH
The policy of CDC is that persons under the age of 21 must
be included in all human subjects research that is conducted
or supported by CDC, unless there are scientific and ethical
reasons not to include them. This policy applies to all
CDC-conducted or CDC-supported research involving human
subjects, including research that is otherwise exempt in
accordance with Sections 101(b) and 401(b) of
45 C.F.R. Part 46, HHS
Policy for the Protection of Human Subjects.
Therefore, proposals for research involving human subjects
must include a description of plans for including persons
under the age of 21. If persons under the age of 21 will be
excluded from the research, the application or proposal must
present an acceptable justification for the exclusion.
In an extramural research plan, the investigator should create a section titled "Participation of persons under the age of 21." This section should provide either a description of the plans to include persons under the age of 21 and a rationale for selecting or excluding a specific age range, or an explanation of the reason(s) for excluding persons under the age of 21 as participants in the research. When persons under the age of 21 are included, the plan must also include a description of the expertise of the investigative team for dealing with individuals at the ages included, the appropriateness of the available facilities to accommodate the included age groups, and the inclusion of a sufficient number of persons under the age of 21 to contribute to a meaningful analysis relative to the purpose of the study. Scientific review groups at CDC will assess each application as being acceptable or unacceptable in regard to the age-appropriate inclusion or exclusion of persons under the age of 21 in the research project, in addition to evaluating the plans for conducting the research in accordance with these provisions.
The inclusion of children (as defined by the applicable law of the jurisdiction in which the research will be conducted) as subjects in research must be in compliance with all applicable subparts of 45 C.F.R. Part 46, as well as with other pertinent federal laws and regulations.
The policy of inclusion of persons under the age of 21 in CDC-conducted or CDC-supported research activities in foreign countries (including collaborative activities) is the same as that for research conducted in the United States.
Public Health System Reporting Requirements
This program is subject to the Public Health System Reporting Requirements. Under these requirements, all community-based non-governmental organizations submitting health services applications must prepare and submit the items identified below to the head of the appropriate State and/or local health agency(s) in the program area(s) that may be impacted by the proposed project no later than the application deadline date of the Federal application. The appropriate State and/or local health agency is determined by the applicant. The following information must be provided:
A. A copy of the face page of the application (SF 424).
B. A summary of the project that should be titled "Public Health System Impact Statement" (PHSIS), not exceed one page, and include the following:
1. A description of the population to be served.
2. A summary of the services to be provided.
3. A description of the coordination plans with the appropriate state and/or local health agencies.
If the State and/or local health official should desire a copy of the entire application, it may be obtained from the State Single Point of Contact (SPOC) or directly from the applicant.
Executive Order 12372 Review
Applications are subject to Intergovernmental Review of Federal Programs, as governed by Executive Order (E.O.) 12372. The order sets up a system for State and local governmental review of proposed Federal assistance applications. Applicants should contact their State single point of contact (SPOC) as early as possible to alert the SPOC to prospective applications and to receive instructions on the State process. For proposed projects serving more than one State, the applicant is advised to contact the SPOC for each State affected.
Click on the following link to get the current SPOC list
http://www.whitehouse.gov/omb/grants/spoc.html
Indian tribes must request tribal government review of their applications.
Specs or tribal governments that have recommendations about an application submitted to HHS/CDC should send them, in a document bearing the program announcement number, no more than 60 days after the application deadline date, to:
Stewart Nichols, Grants Management Specialist
Procurement and Grants Office
Announcement Number IP08-002
Centers for Disease Control and Prevention (CDC)
2920 Brandywine Road
Atlanta, Georgia 30341-4146
HHS/CDC does not guarantee to accept or justify its non-acceptance of recommendations that are received more than 60 days after the application deadline.
Smoke-Free Workplace Requirements
HHS/CDC strongly encourages all recipients to provide a smoke-free workplace and to promote abstinence from all tobacco products. Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, or early childhood development services are provided to children.
The Public Health
Service (PHS) is committed to achieving the health promotion
and disease prevention objectives of "Healthy People 2010,"
a PHS-led national activity for setting priority areas. This
FOA is related to one or more of the priority areas.
Potential applicants may obtain a copy of "Healthy People
2010" at
www.healthypeople.gov
Applicants should be aware of restrictions on the use of HHS funds for lobbying of Federal or State legislative bodies. Under the provisions of 31 U.S.C. Section 1352, recipients (and their sub-tier contractors) are prohibited from using appropriated Federal funds (other than profits from a Federal contract) for lobbying congress or any Federal agency in connection with the award of a particular contract, grant, cooperative agreement, or loan. This includes grants/cooperative agreements that, in whole or in part, involve conferences for which Federal funds cannot be used directly or indirectly to encourage participants to lobby or to instruct participants on how to lobby.
In addition no part of HHS/CDC appropriated funds, shall be used, other than for normal and recognized executive-legislative relationships, for publicity or propaganda purposes, for the preparation, distribution, or use of any kit, pamphlet, booklet, publication, radio, television, or video presentation designed to support or defeat legislation pending before the Congress or any State or local legislature, except in presentation to the Congress or any State or local legislature itself. No part of the appropriated funds shall be used to pay the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence legislation or appropriations pending before the Congress or any State or local legislature.
Any activity designed to influence action in regard to a particular piece of pending legislation would be considered "lobbying." That is lobbying for or against pending legislation, as well as indirect or "grass roots" lobbying efforts by award recipients that are directed at inducing members of the public to contact their elected representatives at the Federal or State levels to urge support of, or opposition to, pending legislative proposals is prohibited. As a matter of policy, HHS/CDC extends the prohibitions to lobbying with respect to local legislation and local legislative bodies.
The provisions are not intended to prohibit all interaction with the legislative branch, or to prohibit educational efforts pertaining to public health. Clearly there are circumstances when it is advisable and permissible to provide information to the legislative branch in order to foster implementation of prevention strategies to promote public health. However, it would not be permissible to influence, directly or indirectly, a specific piece of pending legislation
It remains permissible to use HHS/CDC funds to engage in activity to enhance prevention; collect and analyze data; publish and disseminate results of research and surveillance data; implement prevention strategies; conduct community outreach services; provide leadership and training, and foster safe and healthful environments.
Recipients of HHS/CDC grants and cooperative agreements need to be careful to prevent CDC funds from being used to influence or promote pending legislation. With respect to conferences, public events, publications, and "grassroots" activities that relate to specific legislation, recipients of HHS/CDC funds should give close attention to isolating and separating the appropriate use of HHS/CDC funds from non-CDC funds. HHS/CDC also cautions recipients of HHS/CDC funds to be careful not to give the appearance that HHS/CDC funds are being used to carry out activities in a manner that is prohibited under Federal law.
Prohibition on Use of HHS/CDC Funds for Certain Gun Control Activities
The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act specifies that: "None of the funds made available for injury prevention and control at the Centers for Disease Control and Prevention may be used to advocate or promote gun control."
Anti-Lobbying Act requirements prohibit lobbying Congress with appropriated Federal monies. Specifically, this Act prohibits the use of Federal funds for direct or indirect communications intended or designed to influence a member of Congress with regard to specific Federal legislation. This prohibition includes the funding and assistance of public grassroots campaigns intended or designed to influence members of Congress with regard to specific legislation or appropriation by Congress.
In addition to the restrictions in the Anti-Lobbying Act, HHS/CDC interprets the language in the HHS/CDC's Appropriations Act to mean that HHS/CDC's funds may not be spent on political action or other activities designed to affect the passage of specific Federal, State, or local legislation intended to restrict or control the purchase or use of firearms.
Accounting System Requirements
The services of a certified public accountant licensed by the State Board of Accountancy or the equivalent must be retained throughout the project as a part of the recipient's staff or as a consultant to the recipient's accounting personnel. These services may include the design, implementation, and maintenance of an accounting system that will record receipts and expenditures of Federal funds in accordance with accounting principles, Federal regulations, and terms of the cooperative agreement or grant.
Capability Assessment
It may be necessary to conduct an on-site evaluation of some applicant organization's financial management capabilities prior to or immediately following the award of the grant or cooperative agreement. Independent audit statements from a Certified Public Accountant (CPA) for the preceding two fiscal years may also be required.
Proof of Non-profit Status
Proof of nonprofit status must be submitted by private nonprofit organizations with the application. Any of the following is acceptable evidence of nonprofit status: (a) a reference to the applicant organization's listing in the Internal Revenue Service's (IRS) most recent list of tax-exempt organizations described in section 501(c)(3) of the IRS Code; (b) a copy of a currently valid IRS tax exemption certificate; (c) a statement from a State taxing body, State Attorney General, or other appropriate State Official certifying that the applicant organization has a nonprofit status and that none of the net earnings accrue to any private shareholders or individuals; (d) a certified copy of the organization's certificate of incorporation or similar document that clearly establishes nonprofit status; (e) any of the above proof for a State or national parent organization and a statement signed by the parent organization that the applicant organization is a local nonprofit affiliate.
Research Integrity
The signature of the institution official on the face page of the application submitted under this Funding Opportunity Announcement is certifying compliance with the Department of Health and Human Services (DHHS) regulations in Title 42 Part 93, Subparts A-E, entitled PUBLIC HEALTH SERVICE POLICIES ON RESEARCH MISCONDUCT.
The regulation places requirements on institutions receiving or applying for funds under the PHS Act that are monitored by the DHHS Office of Research Integrity (ORI) (http://ori.hhs.gov./policies/statutes.shtml).
For example:
Section 93.301 Institutional assurances. (a) General policy. An institution with PHS supported biomedical or behavioral research, research training or activities related to that research or research training must provide PHS with an assurance of compliance with this part, satisfactory to the Secretary. PHS funding components may authorize [[Page 28389]] funds for biomedical and behavioral research, research training, or activities related to that research or research training only to institutions that have approved assurances and required renewals on file with ORI. (b) Institutional Assurance. The responsible institutional official must assure on behalf of the institution that the institution-- (1) Has written policies and procedures in compliance with this part for inquiring into and investigating allegations of research misconduct; and (2) Complies with its own policies and procedures and the requirements of this part.
Release and Sharing of Data
The Data Release Plan is the Grantee's assurance that the dissemination of any and all data collected under the HHS/CDC data sharing agreement will be released as follows:
a. In a timely manner.
b. Completely, and as accurately as possible.
c. To facilitate the broader community.
d. Developed in accordance with CDC policy on Releasing and Sharing Data.
April 16, 2003, http://www.cdc.gov/od/foia/policies/sharing.htm, and in full compliance with the 1996 Health Insurance Portability and Accountability Act (HIPPA), (where applicable), The Office of Management and Budget Circular A110, (2000) revised 2003, www.whitehouse.gov/omb/query.html?col=omb&qt=Releasing+and+Sharing+of+Data and Freedom of Information Act (FOIA) http://www.cdc.gov/od/foia/index.htm.
Applications must include a copy of the applicant's Data Release Plan. Applicants should provide HHS/CDC with appropriate documentation on the reliability of the data. Applications submitted without the required Plan may be ineligible for award. Award will be made when reviewing officials have approved an acceptable Plan. The successful applicant and the Program Manager will determine the documentation format. HHS/CDC recommends data is released in the form closest to micro data and one that will preserve confidentiality.
Conference Disclaimer and Use of Logos
Disclaimer: Where a conference is funded by a grant or cooperative agreement, a sub grant or a contract the recipient must include the following statement on conference materials, including promotional materials, agenda, and internet sites:
“Funding for this conference was made possible [in part] by [insert grant or cooperative agreement award number] from the Centers for Disease Control and Prevention(CDC) or the Agency for Toxic Substances and Disease Registry (ATSDR) . The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.”
Logos: Neither the HHS nor the CDC (“CDC” includes ATSDR) logo may be displayed if such display would cause confusion as to the source of the conference or give the false appearance of Government endorsement. A non-federal entity’s unauthorized use of the HHS name or logo is governed by U.S.C. § 1320b-10, which prohibits the misuse of the HHS name and emblem in written communication. The appropriate use of the HHS logo is subject to the review and approval of the Office of the Assistant Secretary for Public Affairs (OASPA). Moreover, the Office of the Inspector General has authority to impose civil monetary penalties for violations (42 C.F.R. Part 1003). Neither the HHS nor the CDC logo can be used on conference materials under a grant, cooperative agreement, contract or co-sponsorship agreement without the expressed, written consent of either the Project Officer or the Grants Management Officer. It is the responsibility of the grantee (or recipient of funds under a cooperative agreement) to request consent for the use of the logo in sufficient detail to assure a complete depiction and disclosure of all uses of the Government logos, and to assure that in all cases of the use of Government logos, the written consent of either the Project Officer or the Grants Management Officer has been received.
CDC Home Page: http://www.cdc.gov
CDC Funding Web Page: http://www.cdc.gov/od/pgo/funding/FOAs.htm
CDC Forms Web Page:
http://www.cdc.gov/od/pgo/funding/grants/app_and_forms.shtm